Silengenics is a biotechnology company focused on developing next-generation therapeutics for complex diseases with high unmet medical need. Our work centers on precision gene silencing approaches to modulate disease-driving pathways with high specificity and durability.

Our pipeline targets key indications in cardiometabolic disorders and immuno-oncology, with a lead program advancing toward proof-of-concept across the spectrum of liver diseases—from MASLD to MASH—alongside dyslipidemia and fibrosis. In parallel, we are developing a broader platform designed to enable scalable and targeted gene regulation across multiple disease areas.

By combining deep biological insight with innovative molecular design, Silengenics aims to unlock new therapeutic possibilities where conventional approaches fall short. Our strategy integrates focused pipeline development with platform expansion to create long-term value in precision medicine.

We collaborate with academic, clinical, and industry partners to accelerate innovation and translate cutting-edge science into impactful therapies.

SILENGENICS

Org chart

Teams

Offices

SILENGENICS

Org chart

Teams

Offices

Related companies